Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

Presentation ACC 2025

Comparison of angiography-derived fractional flow reserve-guided and intravascular ultrasound-guided PCI strategies (FLAVOUR II)

Presenter: Jian’an Wang

March 30, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

Presentation ACC 2019

Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic PCI

Presenter: Allen Jeremias

March 18, 2019

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Presentation ACC 2015

Randomized trial of manual aspiration Thrombectomy + PCI vs_ PCI Alone in STEMI (TOTAL)

Presenter: Sanjit Jolly

March 16, 2015

Presentation ACC 2015

Effect of REG1 Anticoagulation System vs_ Bivalirudin on Cardiovascular Outcomes Following PCI: The REGULATE-PCI Randomized Clinical Trial

Presenter: Roxana Mehran

March 15, 2015

Presentation ACC 2013

Randomized Comparison of PtCr-EES vs CoCr-ZES in All-Comers Receiving PCI: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 08, 2013

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Advertisement

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Comparison of angiography-derived fractional flow reserve-guided and intravascular ultrasound-guided PCI strategies (FLAVOUR II)

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic PCI

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Randomized trial of manual aspiration Thrombectomy + PCI vs_ PCI Alone in STEMI (TOTAL)

Effect of REG1 Anticoagulation System vs_ Bivalirudin on Cardiovascular Outcomes Following PCI: The REGULATE-PCI Randomized Clinical Trial

Randomized Comparison of PtCr-EES vs CoCr-ZES in All-Comers Receiving PCI: The HOST-ASSURE Randomized Trial

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content